Results 131 to 140 of about 108,296 (239)
Abstract Objective Fatigue is highly prevalent in children with inflammatory bowel disease (IBD), even during clinical remission. This suggests a role for transdiagnostic factors—lifestyle, psychological, and social influences not specific to the disease.
Maartje D. Stutvoet +6 more
wiley +1 more source
Prevalence of Cytomegalovirus in Patients With Newly Diagnosed, Flare-Up, and Acute Severe Ulcerative Colitis. [PDF]
Shrestha M +6 more
europepmc +1 more source
Abstract Objectives Deficiency of serum 25‐hydroxyvitamin D [25(OH)D] was associated with decreased short‐term response to anti‐tumor necrosis factor‐alpha (TNF‐α) agents in adults with inflammatory bowel disease (IBD). The aim of this study was to evaluate the association between serum 25(OH)D levels and the outcome of children with IBD undergoing ...
Adi Anafy +6 more
wiley +1 more source
Neovaginal Diversion Colitis Successfully Treated With Mesalazine Suppositories: Endoscopic Documentation of Healing. [PDF]
Kawatoko S, Mori M, Umeno J.
europepmc +1 more source
Abstract Objectives Pediatric patients with chronic gastrointestinal (GI) conditions including inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS) on average endorse lower health related quality of life (HRQOL) than their healthy counterparts.
S. Taylor Younginer +6 more
wiley +1 more source
Analysis of common differential gene expression between rheumatoid arthritis and ulcerative colitis. [PDF]
Han PF, Cui WR, He FZ, Wu T, Liao CS.
europepmc +1 more source
Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Serena Yun‐Chen Tsai +3 more
wiley +1 more source
Immune-Mediated Thrombocytopenia in an Ulcerative Colitis Patient After Initiating Filgotinib Treatment: A Case Report. [PDF]
van der Hoff MJ +2 more
europepmc +1 more source
Real‐world data on STRIDE‐II treatment targets in a pediatric cohort with inflammatory bowel disease
Abstract Objectives STRIDE (selecting therapeutic targets in inflammatory bowel disease) established evidence‐based targets for treat‐to‐target strategies in IBD. STRIDE‐II designates clinical remission, C‐reactive protein (CRP) normalization, and fecal calprotectin (FC) reduction as short‐ to intermediate‐term targets, and mucosal healing as a long ...
Marie‐Luise Frank +9 more
wiley +1 more source

